3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
74
Carcinoma, Neuroendocrine
28
Pheochromocytoma
24
Thyroid Cancer, Papillary
23
Pituitary Neoplasms
22
Thyroid Neoplasms
21
Adrenocortical Carcinoma
19
Paraganglioma
16
Multiple Endocrine Neoplasia Type 1
14
Sarcoma
12
Neuroblastoma
12
Adenoma, Islet Cell
11
Small Cell Lung Carcinoma
10
Neoplasms
10
Melanoma
10
Lung Neoplasms
9
Carcinoid Tumor
9
Adrenal Gland Neoplasms
9
Adenocarcinoma, Follicular
9
Pancreatic Neoplasms
8
Gastro-enteropancreatic neuroendocrine tumor
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Medullary
8
Breast Neoplasms
8
Thyroid Carcinoma, Anaplastic
7
Ovarian Neoplasms
7
Neoplasm Metastasis
7
Mesothelioma
7
Cushing Syndrome
7
Cholangiocarcinoma
7
Interventions
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lethal Congenital Contracture Syndrome 2
×
Endocrine
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled